O. Glehen, F. Mohamed, and F. Gilly, Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia, The Lancet Oncology, vol.5, issue.4, pp.219-228, 2004.
DOI : 10.1016/S1470-2045(04)01425-1

G. Glockzin, H. Schlitt, and P. Piso, Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, World Journal of Surgical Oncology, vol.7, issue.1, p.5, 2009.
DOI : 10.1186/1477-7819-7-5

P. Sugarbaker, Comprehensive management of peritoneal surface malignancy using cytoreductive surgery and perioperative intraperitoneal chemotherapy: the Washington Cancer Institute approach, Expert Opinion on Pharmacotherapy, vol.6, issue.12, pp.1965-1977, 2009.
DOI : 10.1200/JCO.2003.04.187

P. Sugarbaker, W. Cunliffe, J. Belliveau, E. De-bruijn, T. Graves et al., Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer, Semin Oncol, vol.16, pp.83-97, 1989.
DOI : 10.1007/978-2-8178-0782-9_67

D. Elias, F. Gilly, F. Boutitie, F. Quenet, J. Bereder et al., Peritoneal Colorectal Carcinomatosis Treated With Surgery and Perioperative Intraperitoneal Chemotherapy: Retrospective Analysis of 523 Patients From a Multicentric French Study, Journal of Clinical Oncology, vol.28, issue.1, pp.63-68, 2010.
DOI : 10.1200/JCO.2009.23.9285

D. Elias, F. Gilly, F. Quenet, J. Bereder, L. Sidéris et al., Pseudomyxoma peritonei: A French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy, European Journal of Surgical Oncology (EJSO), vol.36, issue.5, pp.456-462, 2010.
DOI : 10.1016/j.ejso.2010.01.006
URL : https://hal.archives-ouvertes.fr/hal-00594804

M. Koppe, R. Bleichrodt, W. Oyen, and O. Boerman, Radioimmunotherapy and colorectal cancer, British Journal of Surgery, vol.256, issue.3, pp.264-76, 2005.
DOI : 10.1002/bjs.4936

F. Aarts, T. Hendriks, O. Boerman, M. Koppe, W. Oyen et al., A Comparison Between Radioimmunotherapy and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Peritoneal Carcinomatosis of Colonic Origin in Rats, Annals of Surgical Oncology, vol.15, issue.11, pp.3274-82, 2007.
DOI : 10.1245/s10434-007-9509-2

F. Aarts, R. Bleichrodt, B. De-man, R. Lomme, O. Boerman et al., The Effects of Adjuvant Experimental Radioimmunotherapy and Hyperthermic Intraperitoneal Chemotherapy on Intestinal and Abdominal Healing after Cytoreductive Surgery for Peritoneal Carcinomatosis in the Rat, Annals of Surgical Oncology, vol.229, issue.11, pp.3299-307, 2008.
DOI : 10.1245/s10434-008-0070-4

M. Koppe, A. Soede, W. Pels, W. Oyen, D. Goldenberg et al., Experimental radioimmunotherapy of small peritoneal metastases of colorectal origin, International Journal of Cancer, vol.50, issue.6, pp.965-972, 2003.
DOI : 10.1002/ijc.11304

S. Kinuya, K. Yokoyama, M. Fukuoka, T. Hiramatsu, H. Mori et al., Intraperitoneal radioimmunotherapy to treat the early phase of peritoneal dissemination of human colon cancer cells in a murine model, Nuclear Medicine Communications, vol.28, issue.2, pp.129-133, 2007.
DOI : 10.1097/MNM.0b013e328013e5a8

J. Elgqvist, H. Andersson, T. Bäck, R. Hultborn, H. Jensen et al., Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35, J Nucl Med, vol.46, pp.1907-1915, 2005.

D. Milenic, E. Brady, K. Garmestani, P. Albert, A. Abdulla et al., Improved efficacy of ??-particle-targeted radiation therapy, Cancer, vol.23, issue.23 suppl, pp.1059-1066, 2010.
DOI : 10.1002/cncr.24793

R. Meredith, D. Buchsbaum, R. Alvarez, and A. Lobuglio, Brief Overview of Preclinical and Clinical Studies in the Development of Intraperitoneal Radioimmunotherapy for Ovarian Cancer, Clinical Cancer Research, vol.13, issue.18, pp.5643-5645, 2007.
DOI : 10.1158/1078-0432.CCR-07-0985

R. Alvarez, W. Huh, M. Khazaeli, R. Meredith, E. Partridge et al., A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer, Clin Cancer Res, vol.8, pp.2806-2811, 2002.

A. Epenetos, V. Hird, H. Lambert, P. Mason, and C. Coulter, Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy, International Journal of Gynecological Cancer, vol.10, issue.s1, pp.44-46, 2000.
DOI : 10.1046/j.1525-1438.2000.99510.x

R. Meredith, E. Partridge, R. Alvarez, M. Khazaeli, G. Plott et al., Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49, J Nucl Med, vol.37, pp.1491-1496, 1996.

V. Hird, A. Maraveyas, D. Snook, B. Dhokia, W. Soutter et al., Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody, British Journal of Cancer, vol.68, issue.2, pp.403-406, 1993.
DOI : 10.1038/bjc.1993.349

S. Nicholson, C. Gooden, V. Hird, A. Maraveyas, P. Mason et al., Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis., Oncology Reports, vol.5, pp.223-226, 1998.
DOI : 10.3892/or.5.1.223

R. Verheijen, L. Massuger, B. Benigno, A. Epenetos, A. Lopes et al., Phase III Trial of Intraperitoneal Therapy With Yttrium-90???Labeled HMFG1 Murine Monoclonal Antibody in Patients With Epithelial Ovarian Cancer After a Surgically Defined Complete Remission, Journal of Clinical Oncology, vol.24, issue.4, pp.571-579, 2006.
DOI : 10.1200/JCO.2005.02.5973

H. Andersson, E. Cederkrantz, T. Bäck, C. Divgi, J. Elgqvist et al., Intraperitoneal ??-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab')2--A Phase I Study, Journal of Nuclear Medicine, vol.50, issue.7, pp.1153-1160, 2009.
DOI : 10.2967/jnumed.109.062604

L. Santoro, S. Boutaleb, V. Garambois, C. Bascoul-mollevi, V. Boudousq et al., Noninternalizing Monoclonal Antibodies Are Suitable Candidates for 125I Radioimmunotherapy of Small-Volume Peritoneal Carcinomatosis, Journal of Nuclear Medicine, vol.50, issue.12, pp.2033-2041, 2009.
DOI : 10.2967/jnumed.109.066993
URL : https://hal.archives-ouvertes.fr/inserm-00442929

J. Pouget, L. Santoro, R. L. Chouin, N. Bardiþs, M. Bascoul-mollevi et al., Cell Membrane is a More Sensitive Target than Cytoplasm to Dense Ionization Produced by Auger Electrons, Radiation Research, vol.170, issue.2, pp.192-200, 2008.
DOI : 10.1667/RR1359.1
URL : https://hal.archives-ouvertes.fr/inserm-00311037

G. Kohler, S. Howe, and C. Milstein, Fusion between immunoglobulin-secreting and nonsecreting myeloma cell lines, European Journal of Immunology, vol.30, issue.4, pp.292-295, 1976.
DOI : 10.1002/eji.1830060411

R. Loevinger, T. Budinger, and E. Watson, MIRD Primer for absorbed dose calculations revised edition, Society of Nuclear Medicine, 1991.

D. Goldenberg, Adjuvant and combined radioimmunotherapy: problems and prospects on the road to Minerva, J Nucl Med, vol.47, pp.1746-1748, 2006.

M. Ychou, D. Azria, P. Faurous, F. Quenet, B. Saint-aubert et al., Adjuvant Radioimmunotherapy Trial with Iodine-131-Labeled Anti-Carcinoembryonic Antigen Monoclonal Antibody F6 F(ab')2 after Resection of Liver Metastases from Colorectal Cancer, Clinical Cancer Research, vol.14, issue.11, pp.3487-93, 2008.
DOI : 10.1158/1078-0432.CCR-07-4698
URL : https://hal.archives-ouvertes.fr/inserm-00292535

S. Denardo, D. Kukis, L. Kroger, O. Donnell, R. Lamborn et al., Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: Efficacy and toxicity in breast cancer xenografts, Proceedings of the National Academy of Sciences, vol.94, issue.8, pp.4000-4004, 1997.
DOI : 10.1073/pnas.94.8.4000

S. Supiot, S. Gouard, J. Charrier, C. Apostolidis, J. Chatal et al., Mechanisms of Cell Sensitization to ?? Radioimmunotherapy by Doxorubicin or Paclitaxel in Multiple Myeloma Cell Lines, Clinical Cancer Research, vol.11, issue.19, pp.7047-7052, 2005.
DOI : 10.1158/1078-0432.CCR-1004-0021

P. Burke, S. Denardo, L. Miers, K. Lamborn, S. Matzku et al., Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts, Cancer Res, vol.62, pp.4263-4272, 2002.

R. Pedley, E. El-emir, A. Flynn, G. Boxer, J. Dearling et al., Synergy between vascular targeting agents and antibody-directed therapy, International Journal of Radiation Oncology*Biology*Physics, vol.54, issue.5, pp.1524-1531, 2002.
DOI : 10.1016/S0360-3016(02)03923-8

J. Chatal, F. Davodeau, M. Cherel, and J. Barbet, Different ways to improve the clinical effectiveness of radioimmunotherapy in solid tumors, Journal of Cancer Research and Therapeutics, vol.5, issue.9, pp.36-40, 2009.
DOI : 10.4103/0973-1482.55139